Status:
COMPLETED
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma
Lead Sponsor:
A.O.U. Città della Salute e della Scienza
Conditions:
Lymphoma, Non-Hodgkin
Hodgkin Lymphoma
Eligibility:
All Genders
19-70 years
Brief Summary
Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac event...
Eligibility Criteria
Inclusion
- Age \>18 years
- Diagnosis of Hodgkin Disease (HD) or Primary Mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL)
- Disease requiring treatment with anthracycline containing regimen only (cohort A) or anthracycline containing regimen followed by mediastinal radiotherapy (cohort B)
- Written informed consent
Exclusion
- Age \> 70 years
- Unable to perform anthracyline containing regimen
- Previous treatment with mediastinal radiotherapy
- Kidney failure (defined as creatinine x2 UNL) or liver failure (defined as AST and ALT x2 UNL)
- ECOG PS \> 2
- Echocardiographic acoustic windows not suitable for strain evaluation
- Any other conditions or situations preventing patients to sign informed consent
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT03480087
Start Date
January 1 2015
End Date
July 1 2022
Last Update
July 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SC Ematologia - AOU Città della salute e della Scienza di Torino
Torino, Italy, 10126